Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Future directions in gastrointestinal cancer

Thorsten Goetze • 26 May 2021
ASCO 2021
Bile Duct Cancer Gastric Cancer Gastrointestinal Cancer Antibodies Bemarituzumab Nivolumab Pembrolizumab

Thorsten O. Goetze, MD, University Cancer Center Frankfurt, Frankfurt, Germany, outlines the changing treatment landscape of patients with gastrointestinal malignancies including combining chemotherapy and immune checkpoint blockade, emerging targeted therapies including the FGFR inhibitor bemarituzumab, as well as HER2-targeting agents in patients with HER2 alternations. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

More from Thorsten Goetze

4:59
Phase I INSIGHT platform trial: eftilagimod alpha with avelumab in advanced solid tumors
Thorsten Goetze • 26 May 2021
1:22
PREVENT: preventive HIPEC in combination with perioperative FLOT for gastric cancer
Thorsten Goetze • 26 May 2021
1:38
NEPAFOX: adjuvant gemcitabine vs. FOLFIRINOX in resectable pancreatic cancer
Thorsten Goetze • 22 Jan 2021
5:13
Gallbladder & bile duct cancer at ASCO GI: GAIN and other highlights
Thorsten Goetze • 22 Jan 2021

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals